top of page

Tacrolimus Pharmacodynamics

Topical Tacrolimus Pharmacodynamics

Tacrolimus (FK506) is a macrolide immunosuppressant that, when used topically, has the following key pharmacodynamic properties:

Mechanism of Action

  • Binds to FKBP (FK506-binding protein), forming a complex that inhibits calcineurin, a calcium-dependent phosphatase

  • This inhibition prevents the dephosphorylation and nuclear translocation of NFAT (Nuclear Factor of Activated T-cells)

  • Blocks T-cell activation and the subsequent production of inflammatory cytokines (IL-2, IL-3, IL-4, IL-5, TNF-α, and IFN-γ)

Immunomodulatory Effects

  • Suppresses T-cell mediated immune responses in the skin

  • Inhibits mast cell and basophil degranulation

  • Reduces the number of inflammatory dendritic cells in the skin

  • Decreases the expression of high-affinity IgE receptors on Langerhans cells

Therapeutic Applications

  • Primarily used for atopic dermatitis (eczema), especially when conventional treatments are ineffective

  • Also effective in other inflammatory skin conditions:

    • Psoriasis

    • Vitiligo

    • Lichen planus

    • Contact dermatitis

Potency

  • Approximately 10-100 times more potent than cyclosporine in inhibiting T-cell activation

  • Available in two concentrations: 0.03% and 0.1% (Protopic®)

  •  

Onset and Duration

  • Improvement typically begins within 1-2 weeks of treatment

  • Maximum effect usually seen after 6-12 weeks of continuous use

  • Long-term intermittent maintenance therapy prevents flares in chronic conditions

Differences from Corticosteroids

  • Does not cause skin atrophy, telangiectasia, or striae

  • No tachyphylaxis (diminishing response with repeated application)

  • Can be used on thin-skinned areas (face, neck, intertriginous areas)

  • Does not affect collagen synthesis

  • Unlike systemic tacrolimus, the topical formulation has minimal systemic absorption, reducing the risk of systemic immunosuppression and other adverse effects associated with oral/IV tacrolimus.

Anchor 1

Topical Tacrolimus Pharmacokinetics

Absorption

  • Penetration: Limited by the large molecular size (822 Da), with minimal penetration through intact skin

  • Enhanced absorption through inflamed or damaged skin due to compromised barrier function

  • Bioavailability: Extremely low (0.5-5%) through intact skin; higher in inflammatory conditions

  • Blood levels: Generally below 1-2 ng/mL with typical use, often below detection limits

  • Regional variation: Higher absorption in areas with thinner stratum corneum (face, neck, genitals, intertriginous areas)

Distribution

  • Binding: >99% bound to plasma proteins, primarily albumin and α1-acid glycoprotein

  • Volume of distribution: Large when systemically absorbed (appx. 1000-1300 L)

  • Tissue distribution: Primarily remains in the epidermis and dermis with minimal systemic distribution

 

Metabolism

  • Primary pathway: CYP3A4 metabolism in the skin and liver (when systemically absorbed)

  • Metabolites: Multiple metabolites with reduced immunosuppressive activity

  • First-pass effect: Significant presystemic metabolism in the skin limits systemic bioavailability

Elimination

  • Half-life: Approximately 35-40 hours for any systemically absorbed drug

  • Clearance: Primarily biliary excretion of metabolites

  • Excretion: <1% excreted unchanged in urine

Concentration-Effect Relationship

  • Therapeutic concentration: Effective local tissue concentrations are achieved despite minimal systemic levels

  • Vehicle effects: Ointment base (Protopic®) enhances skin penetration compared to cream formulations

Special Populations

  • Pediatric: Children (<12 years) may have increased absorption per unit area of application

  • Hepatic impairment: Minimal concern with typical use due to limited systemic absorption

  • Renal impairment: No dosage adjustment needed due to minimal renal elimination

Drug Interactions

  • Topical corticosteroids: May reduce tacrolimus penetration if used concurrently

  • CYP3A4 inhibitors: Potential for increased systemic tacrolimus levels if substantial absorption occurs (rare)

Formulation Factors

  • Ointment vs. cream: Ointment provides better penetration and efficacy

  • Concentration: Available as 0.03% and 0.1%, with proportional pharmacokinetics

  • Application amount: Typical adult application is 2-3 g/day for affected areas

The minimal systemic exposure from topical application explains the favorable safety profile compared to oral tacrolimus, though blood level monitoring may be considered in extensive application or prolonged use.

Tacrolimus Pharmacokinetics

Anchor 3
Anchor 2

Tacrolimus Pivotal Studies - UC

Key Randomized Controlled Trials

Ogata et al. (2006) - First Landmark RCT

  • Design: Multicenter, double-blind, placebo-controlled trial in Japan

  • Participants: 63 patients with steroid-refractory UC

  • Intervention: Oral tacrolimus (target trough levels: high [10-15 ng/mL] vs. low [5-10 ng/mL]) vs. placebo for 2 weeks

  • Results:

    • Clinical improvement: 68.4% (high), 38.1% (low), 10.0% (placebo)

    • Mucosal healing: 78.9% (high), 44.4% (low), 20.0% (placebo)

  • Significance: First RCT demonstrating efficacy of tacrolimus in UC

Ogata et al. (2012) - Long-term Extension

  • Design: Open-label extension study

  • Participants: 62 patients from the initial trial

  • Duration: Up to 12 months

  • Results:

    • Remission rates: 72.5% at week 10, 43.8% at month 12

    • Steroid-free remission: 53.3% of initial responders

  • Significance: Established efficacy for maintenance therapy

​

 

Minami et al. (2015) - Comparative Study

  • Design: Retrospective comparative study

  • Comparison: Tacrolimus vs. anti-TNF therapy in steroid-refractory UC

  • Results:

    • Similar short-term efficacy between tacrolimus and infliximab

    • Faster onset of action with tacrolimus

  • Significance: Positioned tacrolimus as rapid-acting alternative to anti-TNFs

Pivotal Real-World Evidence

Komaki et al. (2016) - Meta-analysis

  • Design: Systematic review and meta-analysis

  • Included: 23 studies with 1,049 patients

  • Results:

    • Short-term clinical response: 55.8% (95% CI: 48.1%-63.3%)

    • Clinical remission: 43.6% (95% CI: 35.2%-52.2%)

  • Significance: Confirmed efficacy across heterogeneous populations

​

 

Yamamoto et al. (2018) - Rescue Therapy Study

  • Design: Multicenter cohort study

  • Participants: 161 hospitalized patients with severe UC

  • Results:

    • Colectomy avoidance: 62.1% at 3 months

    • Higher efficacy in anti-TNF naive patients

  • Significance: Established role in avoiding colectomy in severe cases

Topical Tacrolimus Studies

Lawrance et al. (2008) - Tacrolimus Enemas

  • Design: Open-label pilot study

  • Participants: 12 patients with left-sided UC

  • Intervention: Tacrolimus enemas (0.5 mg/100 mL) for 4 weeks

  • Results:

    • Clinical response: 75%

    • Endoscopic improvement: 67%

  • Significance: Proof-of-concept for topical delivery in distal disease

These pivotal studies established tacrolimus as an effective option for steroid-refractory UC, with particular value as rapid-acting rescue therapy and in patients who have failed or are not candidates for anti-TNF therapy. The evidence supports its use in both induction and maintenance of remission, though long-term safety concerns (particularly nephrotoxicity) have limited its widespread adoption as first-line therapy.

Tacrolimus Adverse Effects

Topical Tacrolimus Adverse Events

Common Local Adverse Events

  • Application site reactions (most frequent)

    • Burning sensation (40-60% of patients)

    • Stinging/pruritus (30-40%)

    • Erythema at application site (20-35%)

    • Warmth or heat sensation (20-30%)

  • Photosensitivity and increased susceptibility to sunburn

  • Skin infections

    • Folliculitis (5-10%)

    • Herpes simplex reactivation (eczema herpeticum)

    • Impetigo and other bacterial infections

Systemic Adverse Events (Rare)

  • Flush reaction with alcohol consumption ("tacrolimus flush")

  • Headache (3-5%)

  • Mild flu-like symptoms (2-3%)

  • Paresthesia (1-2%)

  • Systemic absorption effects (extremely rare with normal use)

    • Nephrotoxicity

    • Neurotoxicity (tremors, headache)

    • Hypertension

    • Hyperglycemia

Special Populations

  • Pediatric concerns

    • Similar adverse event profile to adults

    • Higher rate of skin infections in children under 2 years

  • Pregnancy

    • Limited data, but no clear evidence of teratogenicity

    • Category C medication

Long-Term Safety Concerns

  • Malignancy risk

    • FDA black box warning issued in 2006 regarding potential skin malignancy and lymphoma risk

    • Multiple long-term studies and systematic reviews have not demonstrated significant increased risk

    • Theoretical concern based on systemic immunosuppression effects

  • Photocarcinogenicity

    • Recommendation to avoid excessive UV exposure and use sun protection

Tolerability Features

  • Transient nature of application site reactions

    • Typically diminish after first week of treatment

    • Often correlate with disease severity

  • Management strategies

    • Pre-application cooling

    • Gradual titration of frequency

    • Short-term antihistamine use for pruritus

Monitoring Recommendations

  • Regular skin examinations during long-term therapy

  • No routine blood monitoring required for typical use

  • Blood tacrolimus levels only if extensive application (>30% body surface area) or suspected systemic absorption

Anchor 4
Anchor 5

Tacrolimus Drug Monitoring

Routine Monitoring Parameters

Clinical Monitoring

  • Therapeutic response assessment at 2-4 week intervals initially

  • Adverse event evaluation at each follow-up visit

  • Regular skin examinations for:

    • Local irritation

    • Signs of infection (bacterial, viral, fungal)

    • Skin cancer surveillance during long-term therapy

Laboratory Monitoring

  • Blood tacrolimus levels

    • Not routinely required with standard use

    • Consider if:

      • Application to >30% body surface area

      • Extended use on compromised skin barrier

      • Use in small children or infants

      • Signs of systemic toxicity

    • Target levels: Generally, levels should be undetectable or <2 ng/mL​​​​

Special Situation Monitoring

  • Pediatric patients

    • More frequent follow-up (every 2-4 weeks initially)

    • Growth parameter assessment for extensive long-term use

  • Pregnancy

    • Risk-benefit assessment before initiation

    • Minimal monitoring if used on small areas

Specific Monitoring Protocols

Initial Treatment Phase (1-3 months)

  • Evaluate clinical response every 2-4 weeks

  • Assess for application site reactions

  • Patient education on proper application technique

  • Check for early signs of skin infection

Maintenance Phase

  • Clinical evaluations every 3-6 months

  • Annual dermatologic examination for patients on continuous therapy

  • Intermittent therapy preferred when possible​

High-Risk Scenarios Requiring Enhanced Monitoring

  • Extensive application

    • Consider baseline and periodic tacrolimus levels

    • Monitor for systemic symptoms (headache, paresthesia, GI symptoms)

  • Concomitant systemic immunosuppression

    • Coordinate monitoring with managing specialist

    • Lower threshold for checking tacrolimus levels

  • Facial application

    • Regular skin examinations

    • Strict photoprotection counseling

Patient Self-Monitoring Guidance

  • Recognition of application site reactions vs. infection

  • Awareness of "tacrolimus flush" with alcohol consumption

  • Recording of treatment response

  • Proper documentation of application frequency and quantity

Practical Clinical Approach

  • Most patients require only clinical monitoring without laboratory tests

  • Focus on therapeutic response and local tolerability

  • Minimal systemic absorption means minimal systemic toxicity risk with standard use

  • Pharmacovigilance primarily directed at local effects and long-term skin health

Tacrolimus Drug Drug Interactions

Topical Co-administration Interactions

Enhancers of Absorption

  • Occlusive dressings/wraps: Significantly increase tacrolimus penetration

  • Penetration enhancers: Products containing propylene glycol, ethanol, or other solvents

  • Keratolytic agents: Salicylic acid preparations, alpha/beta hydroxy acids

  • Retinoids: Increase skin permeability by thinning stratum corneum

Antagonistic Interactions

  • Topical corticosteroids: May reduce tacrolimus effectiveness if applied simultaneously

  • Heavy emollients/ointments: Can create barrier that reduces tacrolimus penetration

  • Astringents: Alcohol-based products may inactivate tacrolimus locall​

Systemic Interactions (Primarily Relevant with Extensive Application)

CYP3A4 Inhibitors

  • Azole antifungals: Ketoconazole, itraconazole, fluconazole

  • Macrolide antibiotics: Erythromycin, clarithromycin

  • Calcium channel blockers: Diltiazem, verapamil

  • HIV protease inhibitors: Ritonavir, indinavir

  • Grapefruit juice: Contains furanocoumarin compounds

These may increase systemic tacrolimus levels if significant absorption occurs.

CYP3A4 Inducers

  • Anticonvulsants: Phenytoin, carbamazepine, phenobarbital

  • Rifamycins: Rifampin, rifabutin

  • St. John's Wort: Herbal supplement

These may decrease tacrolimus effectiveness if significant systemic interaction occurs.

Clinical Significance

  • Most drug interactions are of minimal clinical significance with normal topical use due to:

    • Limited systemic absorption

    • Low bioavailability

    • Local rather than systemic action

  • Exceptions where monitoring may be warranted:

    • Extensive application (>30% body surface area)

    • Use on severely inflamed/damaged skin

    • Concomitant use of multiple CYP3A4 inhibitors

    • Pediatric patients with proportionally larger treatment area

Anchor 6

Tacrolimus in Pregnancy

​FDA Pregnancy Classification

  • Historically categorized as Pregnancy Category C (pre-2015 labeling system)

  • Current labeling follows FDA Pregnancy and Lactation Labeling Rule (PLLR)

Available Safety Data

Animal Studies

  • Reproductive studies: Shown embryotoxicity and fetotoxicity at high systemic doses in rats and rabbits

  • Developmental effects: Reduced litter size and increased fetal loss in animal models at doses higher than human therapeutic levels

Human Data

  • Systemic exposure: Very limited with topical use (typically <0.5-5% bioavailability)

  • Registry data: Limited but reassuring

  • Transplant registries: Data from oral tacrolimus in transplant patients shows:

    • No consistent pattern of congenital malformations

    • Increased risk of preterm birth and low birth weight (likely disease-related)

​

Observational Studies

  • Petersen et al. (2018): No significant increase in major malformations

  • Kaplan et al. (2015): Case series of 45 pregnancies found no increase in adverse outcomes

  • UK Transplant Pregnancy Registry: No clear teratogenic signal with systemic tacrolimus

Clinical Recommendations

Risk-Benefit Assessment

  • Limited application area: Consider continuation if treating small areas

  • Extensive disease: Balance maternal benefit vs. theoretical fetal risk

  • Alternative treatments: Consider topical corticosteroids as first-line where appropriate

Monitoring During Pregnancy

  • Clinical monitoring: Regular assessment of disease control

  • Blood levels: Not routinely recommended but consider if extensive use

  • Fetal monitoring: Standard prenatal care adequate for most cases

Lactation Considerations

  • Milk excretion: Minimal levels detected in breast milk with oral tacrolimus

  • Estimated infant exposure: Extremely low with topical maternal use

  • Recommendations: Generally compatible with breastfeeding when used on limited skin areas

Patient Counseling

  • Discuss limited nature of available data

  • Emphasize minimal systemic absorption with normal topical use

  • Share decision-making approach based on disease severity

  • Document discussion in medical record

Anchor 7
Anchor 8

Tacrolimus General References

Pivotal Clinical Trials & Meta-Analyses

  1. Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006;55(9):1255-1262.

  2. Ogata H, Kato J, Hirai F, et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflammatory Bowel Diseases. 2012;18(5):803-808.

  3. Komaki Y, Komaki F, Ido A, et al. Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis. Journal of Crohn's and Colitis. 2016;10(4):484-494.

  4. Baumgart DC, Pintoffl JP, Sturm A, et al. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease—a long-term follow-up. American Journal of Gastroenterology. 2006;101(5):1048-1056.

  5. Yamamoto S, Nakase H, Matsuura M, et al. Efficacy and safety of infliximab as rescue therapy for ulcerative colitis refractory to tacrolimus. Journal of Gastroenterology and Hepatology. 2010;25(5):886-891.​

Topical (Rectal) Tacrolimus Studies

  1. Lawrance IC, Copeland TS. Rectal tacrolimus in the treatment of resistant ulcerative proctitis. Alimentary Pharmacology & Therapeutics. 2008;28(10):1214-1220.

  2. van Dieren JM, van Bodegraven AA, Kuipers EJ, et al. Local application of tacrolimus in distal colitis: feasible and safe. Inflammatory Bowel Diseases. 2009;15(2):193-198.

  3. Schmidt KJ, Herrlinger KR, Emmrich J, et al. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients. Alimentary Pharmacology & Therapeutics. 2013;37(1):129-136.

Comparative Studies

  1. Minami N, Yoshino T, Matsuura M, et al. Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study. BMJ Open Gastroenterology. 2015;2(1):e000021.

  2. Yamamoto T, Shimoyama T, Umegae S, et al. Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study. Alimentary Pharmacology & Therapeutics. 2016;43(6):705-716.

Pharmacokinetics & Dosing Studies

  1. Inoue T, Murano M, Narabayashi K, et al. The clinical safety and efficacy of a novel oral-targeted tacrolimus formulation in patients with severe, active ulcerative colitis. Intestinal Research. 2019;17(4):549-559.

  2. Fellermann K, Ludwig D, Stahl M, et al. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). American Journal of Gastroenterology. 1998;93(10):1860-1866.

pngkey_edited.png
We acknowledge Aboriginal and Torres Strait Islander peoples as the First Australians and Traditional Custodians of the lands where we live, learn and work.
We respect and celebrate First Nations peoples inalienable connection to land and sea.

(02) 4921 4718

HNELHD-IBDPrescription@health.nsw.gov.au

John Hunter Hospital

Lookout Road New Lambton, Newcastle NSW

Copyright Kate Napthali 2024 All rights reserved.

bottom of page